Kathryn L Bilello, MD
Pulmonary Disease · Fresno
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 6
- Since medical school
- 40 years
- New York University School of Medicine, 1986
Offices
6 locations · Central California Faculty Medical Group Inc · Fresno Community Hospital and Medical Center · Community Health Partners
Looking this up.
Hospitals listed: Clovis Community Medical Center · Community Regional Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Bilello’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence G84862 · Current
Licensed to practise in California · since 1998 · expires 2028-06-30 · New York University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Critical Care Medicine
- American Board of Internal Medicine - Internal Medicine
- American Board of Internal Medicine - Pulmonary Disease
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Clovis Community Medical CenterClovis, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Community Medical Centers, which runs 4 hospitalsPatients rate it 3 of 5 · 80% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.7 (12.1 to 17.7) · 421 cases, Jan 2024 – Dec 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.692, Oct 2024 – Sep 2025
- Community Regional Medical CenterFresno, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Community Medical Centers, which runs 4 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 1 of 5 starsWorse than the national rate — Death rate among surgical inpatients with serious treatable complications: 211.21 (174.88 to 247.54) · 239 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.705, Oct 2024 – Sep 2025
See every measure and the patient survey for Clovis Community Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 0 better, 6 the same, 1 worse of 7 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.7 (12.1 to 17.7) · 421 cases | Worse | Jan 2024 – Dec 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.692 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.97 (0.04 to 1.89) · 1,840 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.16 (0.86 to 1.45) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 217.06 (167.45 to 266.67) · 84 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 69 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.1 · 165 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.4 · 161 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 14 · 507 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.6 · 798 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 336 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 3,771 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.39) · 8,649 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.08 to 0.46) · 9,146 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.46 (1.47 to 5.45) · 1,654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.19 (0.61 to 3.78) · 387 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.18 (0.7 to 3.66) · 1,578 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 13.47 (7.08 to 19.87) · 374 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.99 (1.37 to 8.61) · 379 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.58 (0.13 to 3.04) · 405 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.8 (0.23 to 1.38) · 8,198 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 90 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.651 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.922 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.449 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.509 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.3 · 210 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 23 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -1.5 · 152 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 58.4 · 556 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18 · 769 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.8 · 802 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (4 to 7.4) · 421 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.2 · 91 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 93 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 200 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.8 to 15.6) · 2,398 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.1) · 720 cases | No different | Jan 2024 – Dec 2024 |
What patients said (441 patients answered, 26% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 80% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Community Regional Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 1 worse of 8 measures. Safety: 0 better, 7 the same, 0 worse of 7 measures. Readmissions: 0 better, 7 the same, 3 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 211.21 (174.88 to 247.54) · 239 cases | Worse | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.705 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.13 (0.29 to 1.96) · 2,304 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.09 (0.87 to 1.3) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 116 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.7 · 187 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.6 · 445 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.2 · 399 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 582 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 3,744 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.5) · 11,052 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,566 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.33 (1.64 to 5.01) · 3,139 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.08 (0 to 2.3) · 1,423 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.7 (0.52 to 2.88) · 3,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.85 (8.11 to 15.6) · 1,481 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.4 (3.81 to 8.98) · 1,404 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.35 (0.95 to 3.76) · 760 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.64 (0.16 to 1.11) · 10,254 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.817 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.031 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.837 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.81 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.853 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 258 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 689 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 37.4 · 202 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 35.2 · 543 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 39.2 · 434 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.3 · 552 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.6 to 7.9) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.4 (8.3 to 15.4) · 169 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 12.4 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.6 · 248 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.9 (9.5 to 14.9) · 2,590 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 310 cases | No different | Jan 2024 – Dec 2024 |
What patients said (421 patients answered, 26% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$73,213
Medicare paid this office $73,213 for 380 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Critical care, first 30-74 minutes | 68 | $25,076 | $164 |
| Return visit (30+ min) | 123 | $20,785 | $92 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 62 | $7,260 | $93 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 32 | $3,402 | $100 |
| New patient visit (60+ min) | 18 | $3,192 | $177 |
See all 17 services
| Critical care, first 30-74 minutes | 68 | $25,076 | $164 |
| Return visit (30+ min) | 123 | $20,785 | $92 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 62 | $7,260 | $93 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 32 | $3,402 | $100 |
| New patient visit (60+ min) | 18 | $3,192 | $177 |
| New patient visit (45+ min) | 24 | $3,057 | $127 |
| Long return visit (40+ min) | 13 | $2,009 | $144 |
| Test to examine how well the lungs exchange gases | 19 | $909 | $48 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 27 | $882 | $33 |
| Telephone medical discussion with physician, 21-30 minutes | 11 | $842 | $77 |
| Telephone medical discussion with physician, 11-20 minutes | 19 | $791 | $40 |
| Test to determine lung volumes using sensors | 13 | $612 | $47 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 38 | $302 | $8 |
| Test to examine how well the lungs exchange gases | 40 | $268 | $7 |
| Test to determine lung volumes using sensors | 27 | $242 | $9 |
| Test for exercise-induced lung stress | 15 | $224 | $15 |
| Test to measure expiratory airflow and volume | 17 | $108 | $6 |
Who their Medicare patients are
380 Original Medicare patients in 2024. Average age 73 · Under 65 13% · 85 and older 11% · Women 56% · Also on Medicaid 39% · Health risk score 2.39. Above the middle of the specialty; the typical pulmonary disease clinician is at 2.13.
Conditions among them: High blood pressure 75% · COPD 50% · Coronary heart disease 47% · Diabetes 44% · Heart failure 39% · Chronic kidney disease 39% · Depression 30% · Atrial fibrillation 29% · Cancer 22% · Stroke 13% · Dementia 11%.
The office billed $222,504, Medicare allowed $95,831 and paid $73,213; for 845 services of 34 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 380 | 845 | 73 | 2.39 | $222,504 | $73,213 |
| 2023 | 338 | 745 | 72 | 2.32 | $201,006 | $66,924 |
| 2022 | 434 | 979 | 72 | 2.23 | $254,519 | $83,076 |
| 2021 | 356 | 719 | 71 | 2.58 | $238,000 | $72,155 |
| 2020 | 403 | 754 | 72 | 2.59 | $196,063 | $65,496 |
| 2019 | 482 | 947 | 72 | 2.71 | $239,474 | $78,254 |
| 2018 | 411 | 879 | 71 | 2.42 | $229,124 | $74,549 |
| 2017 | 421 | 840 | 71 | 2.53 | $231,387 | $75,452 |
| 2016 | 405 | 783 | 72 | 2.35 | $198,049 | $66,379 |
| 2015 | 425 | 914 | 71 | 2.35 | $308,860 | $99,953 |
| 2014 | 404 | 879 | 70 | 2.05 | $278,809 | $88,100 |
| 2013 | 432 | 936 | 70 | 2.44 | $317,276 | $100,288 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 14 services
| Critical care, first 30-74 minutes | 58 | $22,996 | $172 |
| Return visit (30+ min) | 122 | $20,568 | $96 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 45 | $4,763 | $104 |
| New patient visit (45+ min) | 31 | $4,131 | $133 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $2,814 | $97 |
| Test to examine how well the lungs exchange gases | 25 | $1,225 | $49 |
| Short return visit (20+ min) | 17 | $1,161 | $68 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 28 | $894 | $32 |
| Test to determine lung volumes using sensors | 16 | $747 | $47 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 24 | $195 | $8 |
| Test for exercise-induced lung stress | 11 | $194 | $18 |
| Test to determine lung volumes using sensors | 19 | $181 | $10 |
| Test to examine how well the lungs exchange gases | 24 | $169 | $7 |
| Test to measure expiratory airflow and volume | 14 | $91 | $6 |
2022: 17 services
| Critical care, first 30-74 minutes | 100 | $34,723 | $170 |
| Return visit (30+ min) | 132 | $22,440 | $99 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 36 | $3,994 | $108 |
| New patient visit (45+ min) | 31 | $3,730 | $120 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 37 | $3,263 | $76 |
| Test to examine how well the lungs exchange gases | 40 | $2,001 | $50 |
| Test to determine lung volumes using sensors | 33 | $1,531 | $46 |
| Short return visit (20+ min) | 19 | $1,482 | $74 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 38 | $1,225 | $32 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $744 | $57 |
| Test for exercise-induced lung stress | 15 | $414 | $28 |
| Test for exercise-induced lung stress | 22 | $345 | $16 |
| Test to determine lung volumes using sensors | 38 | $333 | $9 |
| Test to measure expiratory airflow and volume | 13 | $294 | $23 |
| Test to examine how well the lungs exchange gases | 46 | $282 | $6 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 41 | $277 | $7 |
| Test to measure expiratory airflow and volume | 15 | $107 | $7 |
2021: 13 services
| Critical care, first 30-74 minutes | 116 | $44,768 | $177 |
| Return visit (30+ min) | 51 | $6,325 | $102 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 32 | $3,341 | $104 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 33 | $3,051 | $85 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 29 | $2,219 | $77 |
| Test to examine how well the lungs exchange gases | 27 | $1,388 | $51 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 33 | $1,279 | $39 |
| Test to determine lung volumes using sensors | 24 | $1,100 | $46 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,002 | $59 |
| Test to determine lung volumes using sensors | 24 | $220 | $9 |
| Test to examine how well the lungs exchange gases | 30 | $207 | $7 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 25 | $205 | $8 |
| Test to measure expiratory airflow and volume | 20 | $131 | $6 |
2020: 17 services
| Critical care, first 30-74 minutes | 77 | $29,770 | $183 |
| Return visit (30+ min) | 97 | $10,399 | $83 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 36 | $3,781 | $105 |
| Telephone medical discussion with physician, 21-30 minutes | 34 | $3,069 | $88 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 29 | $2,952 | $59 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 19 | $2,182 | $87 |
| New patient visit (45+ min) | 13 | $1,722 | $132 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 20 | $1,581 | $79 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 30 | $1,512 | $47 |
| Test to examine how well the lungs exchange gases | 18 | $938 | $49 |
| Test to determine lung volumes using sensors | 18 | $842 | $47 |
| Counseling visit to discuss need for lung cancer screening using low dose ct scan (ldct) (service is for eligibility determination and shared decision making) | 21 | $638 | $30 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 33 | $348 | $11 |
| Test to determine lung volumes using sensors | 30 | $302 | $10 |
| Test to examine how well the lungs exchange gases | 37 | $274 | $7 |
| Test for exercise-induced lung stress | 11 | $210 | $19 |
| Test to measure expiratory airflow and volume | 16 | $112 | $7 |
2019: 17 services
| Critical care, first 30-74 minutes | 86 | $28,453 | $175 |
| Return visit (30+ min) | 128 | $17,739 | $83 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 48 | $5,076 | $106 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 39 | $4,785 | $57 |
| New patient visit (45+ min) | 33 | $4,152 | $126 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 34 | $3,189 | $84 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $2,690 | $149 |
| Return visit (30+ min) | 25 | $1,529 | $61 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 26 | $1,272 | $49 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 16 | $1,261 | $79 |
| Test to examine how well the lungs exchange gases | 16 | $749 | $47 |
| Test to determine lung volumes using sensors | 14 | $637 | $45 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 41 | $427 | $10 |
| Test to determine lung volumes using sensors | 38 | $383 | $10 |
| Test to examine how well the lungs exchange gases | 49 | $358 | $7 |
| Counseling visit to discuss need for lung cancer screening using low dose ct scan (ldct) (service is for eligibility determination and shared decision making) | 11 | $321 | $29 |
| Test to measure expiratory airflow and volume | 16 | $110 | $7 |
2018: 16 services
| Critical care, first 30-74 minutes | 54 | $25,005 | $179 |
| Return visit (30+ min) | 144 | $20,728 | $80 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 48 | $4,442 | $58 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 39 | $4,301 | $108 |
| New patient visit (45+ min) | 30 | $3,754 | $125 |
| Return visit (30+ min) | 47 | $3,060 | $59 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $1,434 | $84 |
| Long return visit (40+ min) | 12 | $1,139 | $88 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 16 | $823 | $51 |
| New patient visit (30+ min) | 14 | $814 | $58 |
| Test to examine how well the lungs exchange gases | 19 | $771 | $41 |
| Test to determine lung volumes using gas dilution or washout | 13 | $484 | $37 |
| Test to determine lung volumes using gas dilution or washout | 27 | $272 | $10 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 23 | $245 | $11 |
| Test to examine how well the lungs exchange gases | 30 | $224 | $7 |
| Test to measure expiratory airflow and volume | 11 | $76 | $7 |
2017: 15 services
| Critical care, first 30-74 minutes | 88 | $27,925 | $176 |
| Return visit (30+ min) | 119 | $17,213 | $79 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 76 | $8,271 | $106 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 39 | $4,547 | $57 |
| New patient visit (45+ min) | 27 | $3,288 | $122 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 31 | $2,819 | $81 |
| Long return visit (40+ min) | 16 | $1,744 | $109 |
| Return visit (30+ min) | 26 | $1,562 | $60 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 19 | $928 | $49 |
| New patient visit (30+ min) | 13 | $726 | $56 |
| Test to examine how well the lungs exchange gases | 14 | $634 | $45 |
| Test to determine lung volumes using gas dilution or washout | 11 | $382 | $35 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 30 | $299 | $10 |
| Test to determine lung volumes using gas dilution or washout | 25 | $242 | $10 |
| Test to examine how well the lungs exchange gases | 27 | $188 | $7 |
2016: 13 services
| Critical care, first 30-74 minutes | 68 | $25,093 | $178 |
| Return visit (30+ min) | 138 | $16,728 | $83 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 45 | $4,983 | $111 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 40 | $4,443 | $58 |
| New patient visit (45+ min) | 26 | $3,325 | $128 |
| Long return visit (40+ min) | 19 | $2,254 | $119 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $1,939 | $162 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $1,685 | $84 |
| New patient visit (30+ min) | 14 | $1,037 | $74 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 52 | $567 | $11 |
| Test to determine lung volumes using gas dilution or washout | 41 | $404 | $10 |
| Test to examine how well the lungs exchange gases | 44 | $322 | $7 |
| Test to measure expiratory airflow and volume | 21 | $145 | $7 |
2015: 12 services
| Critical care, first 30-74 minutes | 118 | $53,339 | $178 |
| Return visit (30+ min) | 122 | $16,812 | $81 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 67 | $7,438 | $108 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 56 | $6,196 | $84 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $4,389 | $163 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 32 | $3,052 | $58 |
| New patient visit (45+ min) | 22 | $2,939 | $134 |
| New patient visit (30+ min) | 14 | $1,227 | $88 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 30 | $332 | $11 |
| Test to determine lung volumes using gas dilution or washout | 27 | $263 | $10 |
| Test to examine how well the lungs exchange gases | 28 | $202 | $7 |
| Test to measure expiratory airflow and volume | 13 | $90 | $7 |
2014: 12 services
| Critical care, first 30-74 minutes | 105 | $44,235 | $179 |
| Return visit (30+ min) | 121 | $15,817 | $80 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 58 | $7,127 | $84 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 45 | $4,983 | $111 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $3,644 | $158 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 33 | $3,489 | $58 |
| New patient visit (45+ min) | 20 | $2,508 | $125 |
| New patient visit (30+ min) | 15 | $1,230 | $82 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 43 | $449 | $10 |
| Test to determine lung volumes using gas dilution or washout | 32 | $313 | $9 |
| Test to examine how well the lungs exchange gases | 34 | $247 | $7 |
| Test to measure expiratory airflow and volume | 26 | $179 | $7 |
2013: 12 services
| Critical care, first 30-74 minutes | 115 | $53,912 | $173 |
| Return visit (30+ min) | 150 | $19,935 | $84 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 69 | $6,774 | $81 |
| New patient visit (45+ min) | 38 | $4,918 | $129 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 34 | $3,654 | $107 |
| Long return visit (40+ min) | 15 | $1,860 | $109 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $1,129 | $56 |
| Administration of influenza virus vaccine | 15 | $405 | $27 |
| Test to determine lung volumes using gas dilution or washout | 27 | $284 | $11 |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) | 16 | $230 | $14 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 23 | $230 | $10 |
| Test to examine how well the lungs exchange gases | 25 | $190 | $8 |
Medicaid work
$13,726 in 2024
Medicaid paid $13,726 for 432 billed services this clinician did in 2024, up to 28 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 185 | $5,789 |
| Clinic visit/encounter, all-inclusive | 13 | $4,680 |
| Diffusing capacity | 67 | $1,220 |
| EVALUATION OF WHEEZING | 52 | $942 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 85 | $832 |
| Plethysmography for determination of lung volumes and, when performed, airway resistance | 30 | $264 |
| 2024 | 432 | 6 | 28 | $13,726 |
| 2023 | 364 | 6 | 21 | $10,211 |
| 2022 | 508 | 6 | 27 | $12,085 |
| 2021 | 176 | 4 | 23 | $6,293 |
| 2020 | 259 | 4 | 22 | $15,489 |
| 2019 | 204 | 3 | 22 | $12,890 |
| 2018 | 180 | 6 | 22 | $1,835 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 13 | $4,509 |
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 183 | $3,674 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 52 | $916 |
| EVALUATION OF WHEEZING | 50 | $491 |
| Diffusing capacity | 50 | $448 |
| Plethysmography for determination of lung volumes and, when performed, airway resistance | 16 | $173 |
2022
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 255 | $8,115 |
| Clinic visit/encounter, all-inclusive | 12 | $3,623 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 31 | $256 |
| EVALUATION OF WHEEZING | 72 | $42 |
| Plethysmography for determination of lung volumes and, when performed, airway resistance | 66 | $29 |
| Diffusing capacity | 72 | $20 |
2021
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 135 | $6,113 |
| Diffusing capacity | 15 | $63 |
| EVALUATION OF WHEEZING | 14 | $59 |
| Plethysmography for determination of lung volumes and, when performed, airway resistance | 12 | $58 |
2020
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 204 | $10,715 |
| Clinic visit/encounter, all-inclusive | 14 | $3,990 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 26 | $392 |
| IP/OBS CONSLTJ NEW/EST PT LOW MDM 45 MINUTES | 15 | $391 |
2019
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 133 | $7,756 |
| Clinic visit/encounter, all-inclusive | 18 | $3,902 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 53 | $1,232 |
2018
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 68 | $910 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 56 | $519 |
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 14 | $260 |
| EVALUATION OF WHEEZING | 14 | $76 |
| Gas dilution or washout for determination of lung volumes and, when performed, distribution of ventilation and closing volumes | 14 | $43 |
| Diffusing capacity | 14 | $28 |
Drugs they prescribed that Part D paid
$178,519
Pharmacies billed $178,519 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 614) in 2024. At or below the middle of the specialty; the typical pulmonary disease clinician is at 0%.
355 generic and fewer than 11 brand-name prescriptions · $178,519 in drug cost · 87 antibiotic prescriptions to 37 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Trelegy Ellipta | 71 | $52,053 | $733 |
| Dupixent | 12 | $46,022 | $3,835 |
| Breo Ellipta | 67 | $25,867 | $386 |
| Breztri Aerosphere | 26 | $18,393 | $707 |
| Stiolto Respimat | 16 | $7,273 | $455 |
See all 15 drugs
| Trelegy Ellipta | 71 | $52,053 | $733 |
| Dupixent | 12 | $46,022 | $3,835 |
| Breo Ellipta | 67 | $25,867 | $386 |
| Breztri Aerosphere | 26 | $18,393 | $707 |
| Stiolto Respimat | 16 | $7,273 | $455 |
| Breyna | 11 | $1,914 | $174 |
| Albuterol Sulfate Hfa | 41 | $1,286 | $31 |
| Wixela Inhub | 13 | $1,175 | $90 |
| Montelukast | 49 | $720 | $15 |
| Prednisone | 68 | $432 | $6 |
| Azithromycin | 37 | $284 | $8 |
| Pantoprazole | 32 | $224 | $7 |
| Fluticasone Propionate | 18 | $216 | $12 |
| Amoxicillin-Clavulanate Potass | 23 | $211 | $9 |
| Levofloxacin | 18 | $122 | $7 |
Year by year
| 2024 | 614 | 110 | 0% (0) | None | $178,519 |
| 2023 | 610 | 113 | 0% (0) | None | $273,694 |
| 2022 | 667 | 112 | 0% (0) | 54% | $398,207 |
| 2021 | 513 | 84 | 0% (0) | 58% | $425,216 |
| 2020 | 628 | 116 | 0% (0) | 51% | $442,184 |
| 2019 | 488 | 101 | 0% (0) | 52% | $130,680 |
| 2018 | 408 | 95 | 0% (0) | 49% | $92,632 |
| 2017 | 352 | 86 | None | 57% | $71,338 |
| 2016 | 385 | 70 | None | 54% | $83,464 |
| 2015 | 325 | 61 | None | 48% | $57,553 |
| 2014 | 385 | 59 | None | 49% | $60,590 |
| 2013 | 375 | 58 | 0% (0) | 47% | $45,059 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 14 drugs
| Trelegy Ellipta | 74 | $69,178 | $935 |
| Dupixent | 12 | $43,417 | $3,618 |
| Breo Ellipta | 47 | $26,194 | $557 |
| Symbicort | 28 | $15,816 | $565 |
| Stiolto Respimat | 12 | $6,884 | $574 |
| Advair Diskus | 14 | $5,849 | $418 |
| Albuterol Sulfate Hfa | 46 | $1,739 | $38 |
| Ventolin Hfa | 14 | $1,237 | $88 |
| Azithromycin | 55 | $741 | $13 |
| Montelukast | 34 | $609 | $18 |
| Famotidine | 15 | $345 | $23 |
| Fluticasone Propionate | 14 | $336 | $24 |
| Prednisone | 61 | $332 | $5 |
| Pantoprazole | 18 | $226 | $13 |
2022: 21 drugs
| Arikayce | 15 | $205,220 | $13,681 |
| Trelegy Ellipta | 84 | $79,031 | $941 |
| Breo Ellipta | 39 | $20,571 | $527 |
| Advair Diskus | 21 | $10,548 | $502 |
| Combivent Respimat | 13 | $8,374 | $644 |
| Advair Hfa | 14 | $7,816 | $558 |
| Fluticasone-Vilanterol | 13 | $6,691 | $515 |
| Anoro Ellipta | 12 | $5,465 | $455 |
| Symbicort | 12 | $5,292 | $441 |
| Stiolto Respimat | 11 | $5,085 | $462 |
| Albuterol Sulfate Hfa | 68 | $2,997 | $44 |
| Ventolin Hfa | 29 | $2,091 | $72 |
| Azithromycin | 41 | $1,532 | $37 |
| Rifampin | 18 | $911 | $51 |
| Montelukast | 42 | $897 | $21 |
| Ipratropium | 13 | $428 | $33 |
| Prednisone | 53 | $360 | $7 |
| Pantoprazole | 25 | $266 | $11 |
| Fluticasone Propionate | 22 | $253 | $12 |
| Famotidine | 12 | $160 | $13 |
| Levofloxacin | 16 | $70 | $4 |
2021: 12 drugs
| Arikayce | 20 | $249,047 | $12,452 |
| Trelegy Ellipta | 46 | $34,535 | $751 |
| Breo Ellipta | 56 | $30,049 | $537 |
| Combivent Respimat | 28 | $16,918 | $604 |
| Spiriva Respimat | 21 | $15,544 | $740 |
| Advair Diskus | 21 | $13,106 | $624 |
| Albuterol Sulfate Hfa | 78 | $3,316 | $43 |
| Ventolin Hfa | 15 | $1,638 | $109 |
| Montelukast | 28 | $847 | $30 |
| Azithromycin | 25 | $597 | $24 |
| Prednisone | 32 | $374 | $12 |
| Fluticasone Propionate | 12 | $113 | $9 |
2020: 18 drugs
| Arikayce | 23 | $274,878 | $11,951 |
| Nucala | 11 | $32,568 | $2,961 |
| Breo Ellipta | 47 | $31,963 | $680 |
| Trelegy Ellipta | 35 | $23,688 | $677 |
| Spiriva Respimat | 15 | $9,595 | $640 |
| Advair Diskus | 11 | $9,508 | $864 |
| Symbicort | 15 | $7,103 | $474 |
| Anoro Ellipta | 15 | $6,578 | $439 |
| Albuterol Sulfate Hfa | 77 | $3,710 | $48 |
| Ventolin Hfa | 26 | $2,273 | $87 |
| Proair Hfa | 26 | $1,943 | $75 |
| Azithromycin | 42 | $1,375 | $33 |
| Rifampin | 14 | $1,058 | $76 |
| Montelukast | 40 | $866 | $22 |
| Ethambutol | 16 | $477 | $30 |
| Prednisone | 61 | $477 | $8 |
| Fluticasone Propionate | 11 | $183 | $17 |
| Pantoprazole | 12 | $140 | $12 |
2019: 15 drugs
| Breo Ellipta | 47 | $32,816 | $698 |
| Trelegy Ellipta | 18 | $11,056 | $614 |
| Advair Diskus | 17 | $10,223 | $601 |
| Spiriva Respimat | 19 | $9,496 | $500 |
| Stiolto Respimat | 13 | $7,875 | $606 |
| Anoro Ellipta | 18 | $7,409 | $412 |
| Ventolin Hfa | 35 | $2,777 | $79 |
| Proair Hfa | 21 | $1,760 | $84 |
| Albuterol Sulfate Hfa | 22 | $1,112 | $51 |
| Montelukast | 26 | $621 | $24 |
| Azithromycin | 23 | $426 | $19 |
| Prednisone | 48 | $352 | $7 |
| Fluticasone Propionate | 16 | $251 | $16 |
| Omeprazole | 12 | $178 | $15 |
| Fluconazole | 16 | $93 | $6 |
2018: 11 drugs
| Breo Ellipta | 63 | $32,678 | $519 |
| Advair Diskus | 16 | $11,864 | $741 |
| Anoro Ellipta | 21 | $8,360 | $398 |
| Spiriva | 11 | $7,040 | $640 |
| Ventolin Hfa | 33 | $2,478 | $75 |
| Proair Hfa | 12 | $1,037 | $86 |
| Montelukast | 33 | $875 | $27 |
| Azithromycin | 34 | $511 | $15 |
| Prednisone | 44 | $293 | $7 |
| Levofloxacin | 16 | $265 | $17 |
| Fluticasone Propionate | 16 | $184 | $11 |
2017: 12 drugs
| Breo Ellipta | 61 | $25,233 | $414 |
| Spiriva | 13 | $7,570 | $582 |
| Advair Diskus | 11 | $6,494 | $590 |
| Symbicort | 14 | $6,429 | $459 |
| Anoro Ellipta | 12 | $4,437 | $370 |
| Ventolin Hfa | 39 | $2,489 | $64 |
| Proair Hfa | 16 | $1,681 | $105 |
| Montelukast | 18 | $600 | $33 |
| Levetiracetam | 12 | $286 | $24 |
| Levofloxacin | 12 | $262 | $22 |
| Prednisone | 27 | $235 | $9 |
| Azithromycin | 18 | $189 | $11 |
2016: 13 drugs
| Advair Diskus | 42 | $25,158 | $599 |
| Breo Ellipta | 45 | $20,515 | $456 |
| Spiriva | 20 | $10,318 | $516 |
| Advair Hfa | 11 | $4,104 | $373 |
| Ventolin Hfa | 34 | $2,488 | $73 |
| Proair Hfa | 11 | $695 | $63 |
| Sucralfate | 11 | $271 | $25 |
| Azithromycin | 22 | $243 | $11 |
| Levetiracetam | 14 | $235 | $17 |
| Prednisone | 26 | $224 | $9 |
| Fluticasone Propionate | 19 | $219 | $12 |
| Omeprazole | 13 | $58 | $4 |
| Hydrochlorothiazide | 11 | $18 | $2 |
2015: 13 drugs
| Advair Diskus | 43 | $22,960 | $534 |
| Spiriva | 19 | $10,029 | $528 |
| Breo Ellipta | 17 | $5,603 | $330 |
| Advair Hfa | 13 | $3,894 | $300 |
| Ventolin Hfa | 12 | $800 | $67 |
| Proair Hfa | 11 | $729 | $66 |
| Azithromycin | 36 | $561 | $16 |
| Levofloxacin | 15 | $318 | $21 |
| Sucralfate | 13 | $296 | $23 |
| Prednisone | 29 | $275 | $9 |
| Fluticasone Propionate | 18 | $225 | $12 |
| Levetiracetam | 12 | $197 | $16 |
| Omeprazole | 13 | $70 | $5 |
2014: 15 drugs
| Advair Diskus | 58 | $25,653 | $442 |
| Spiriva | 23 | $8,872 | $386 |
| Pradaxa | 28 | $3,955 | $141 |
| Advair Hfa | 11 | $3,213 | $292 |
| Proair Hfa | 19 | $942 | $50 |
| Azithromycin | 21 | $729 | $35 |
| Ventolin Hfa | 11 | $528 | $48 |
| Sucralfate | 13 | $433 | $33 |
| Montelukast | 17 | $414 | $24 |
| Fluticasone Propionate | 17 | $388 | $23 |
| Prednisone | 34 | $303 | $9 |
| Amoxicillin | 13 | $150 | $12 |
| Omeprazole | 13 | $123 | $9 |
| Prochlorperazine Maleate | 11 | $69 | $6 |
| Alprazolam | 13 | $42 | $3 |
2013: 13 drugs
| Advair Diskus | 43 | $16,140 | $375 |
| Spiriva | 12 | $3,833 | $319 |
| Pradaxa | 34 | $2,231 | $66 |
| Flovent Hfa | 12 | $2,000 | $167 |
| Azithromycin | 26 | $816 | $31 |
| Proair Hfa | 16 | $790 | $49 |
| Montelukast | 19 | $717 | $38 |
| Ventolin Hfa | 12 | $663 | $55 |
| Fluticasone Propionate | 23 | $623 | $27 |
| Sucralfate | 12 | $387 | $32 |
| Omeprazole | 18 | $216 | $12 |
| Amoxicillin | 12 | $142 | $12 |
| Prednisone | 17 | $43 | $3 |
Money from drug and device companies
$24 in 2025
| 2025 | 1 | 1 | None | $24 |
| 2023 | 2 | 4 | None | $72 |
| 2022 | 2 | 3 | None | $45 |
| 2021 | 1 | 2 | None | $32 |
| 2020 | 1 | 3 | None | $144 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Amgen | Tezspire | $24 | 1 payment
|
See the published payment
| Amgen | Meals · 2025-03-22 | Tezspire | $24 |
See earlier years (2023, 2022, 2021, 2020)
2023: $72
| Boehringer Ingelheim Pharmaceuticals | Ofev | $43 | 2 payments
|
| GlaxoSmithKline | Nucala | $29 | 2 payments
|
2022: $45
| GlaxoSmithKline | Nucala | $29 | 2 payments
|
| Insmed | Arikayce | $16 | 1 payment
|
2021: $32
| Insmed | Arikayce | $32 | 2 payments
|
2020: $144
| GlaxoSmithKline | Nucala | $144 | 3 payments
|
Professional record
- NPI
- 1366461816
- Licence
- CA G84862California G84862: Current · expires 2028-06-30
- Trained
- New York University School of Medicine, 1986 · 40 years ago
- Group
- Central California Faculty Medical Group Inc · Fresno Community Hospital and Medical Center · Community Health Partners
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RP1001X (207RP1001X); Internal medicine (207R00000X); Federal specialty code 207RC0200X (207RC0200X)
- Mailing address
- 2625 E Divisadero St, Fresno, CA, 93721
- NPI first listed
- 2006-07-18
- NPI last updated
- 2025-03-19
- NPI record certified
- 2025-03-19
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 726 N Medical Center Dr E Ste 201, Clovis, CA, 93611